NASHVILLE, Tenn. -- Racial biases persist in the use of pulse oximetry devices for patients with acute hypoxemic respiratory failure (AHRF) requiring very high levels of oxygen support, a ...

Correspondence to Dr Hideo Ohuchi, Department of Paediatric Cardiology, National Cerebral and Cardiovascular Centre, 5-7-1, Fujishiro-dai, Suita, Osaka 565-8565, Japan; hohuchi{at}hsp.ncvc.go.jp ...

Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos. Cytokinetics has won FDA approval of its ...

An ABG test checks how well your lungs and kidneys work by measuring oxygen and carbon dioxide in your blood. This test helps doctors know if your body has an acid-base balance issue and if treatment ...

本刊编辑推荐：为解决当前基于血红蛋白（Hb）的输血策略在稳定期癌症贫血患者中可能无法准确反映组织氧合状态的问题，研究人员开展了一项前瞻性观察研究，主题为评估氧摄取率（O2ER）等生理学指标作为替代输血触发因素的可行性。研究结果表明，基线O2ER ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

“This is a historic moment for our company and for the patients we serve, as we fulfill our promise to translate our science into medicines that may make a meaningful difference in patients’ lives,” ...

The shares of biotechnology firm Cytokinetics are approaching what may be one of the most consequential weeks in the company’s recent timeline. Investor attention is intensely focused on an imminent ...

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO® (aficamten) has been approved by the China National Medical ...